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Herbal Remedies Are Not Dietary Supplements: A
Proposal For Regulatory Reform
Cary Elizabeth Zuk*
INTRODUCTION
Americans are increasingly using herbal products to improve health.'
The annual retail market for herbal products is close to $4 billion, up from
$839 million in 1991 and growing about eighteen percent per year.2 In
partial response to the demand of consumers of herbal products and the
herbal products industry,3 the federal government enacted the Dietary
Supplement Health and Education Act (DSHEA)4 in 1994. For many
DSHEA signals the beginning of a new regulatory era in which the Food
and Drug Administration (FDA) must balance its duty to protect consumers
from unsafe and ineffective products against the consumer's interest in
access to products and non-misleading information about the health
* B.A., University of California, Santa Barbara (1997); J.D. candidate, University of
California, Hastings College of the Law, class of 2000. I thank Deborah King, Heather
Kirlin, Micha Star Liberty, Michelle Madriaga, Sarah Ream, Michelle Rutledge, Penelope
Shaner-Gaffney and Dominique Tauzin. A special thanks to my parents, and also to
Professor Marsha N. Cohen for her substantive review.
1. See Jane E. Brody, Americans Gamble on Herbs as Medicine: With Few Regulations,
No Guarantee of Quality, N.Y. TIMES, Feb. 9, 1999, at D1 [hereinafter Brody, Americans
Gamble].
2. See id.
3. See Michael Higgins, Hard to Swallow: While Federal Law Shut the Door on
Regulation of Dietary Supplements, Marketing Hype May be Leading the Popular Aids Up
Courthouse Steps, A.B.A. J., June 1999, at 60, 61.
4. Pub. L. No. 103-417, 108 Stat. 4325 (1994), reprinted in COMM'N ON DIETARY
SUPPLEMENT LABELS, REPORT OF THE COMMISSION ON DIETARY SUPPLEMENT LABELS A-1
(1997) [hereinafter COMMISSION REPORT]. Sections 1 through 9 of the Dietary Supplement
Health and Education Act amended the Federal Food, Drug, and Cosmetic Act. Id. § 1. For
reference, section 1 amends 21 U.S.C. § 301. Id. Section 2 appears as a note in 21 U.S.C. §
321. Section 3(a) amends 21 U.S.C. § 321, and section 3(b) amends 21 U.S.C. § 321(s). Id.
§ 3, 108 Stat. at 4327. Section 4 amends 21 U.S.C. § 342. Id. § 4, 108 Stat. at 4328.
Section 5 appears as 21 U.S.C. § 343-2. Id. Section 6 amends 21 U.S.C. § 343(r). Id. § 6,
108 Stat. at 4329. Section 7(a) amends 21 U.S.C. § 343, and Section 7(b) amends 21 U.S.C.
§ 343(q)(5)(F). Id. § 7, 108 Stat. at 4329-30. Section 7(c) amends 21 U.S.C. § 403(r)(2).
Id. Section 8 appears as 21 U.S.C. § 350(b). Id. § 8, 108 Stat. at 4331. And Section 9
amends 21 U.S.C. § 342. Id. § 9, 108 Stat. at 4332.
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benefits of those products.5 Under DSHEA, herbal remedies like Kava
Kava6 and Ephedra7 can enter the market as dietary supplements with
labeling statements claiming a positive effect on the structure or function of
the body (structure-function claims), or on one's general sense of well-
being. The FDA has no authority to interfere with herbal remedies that
comply with DSHEA. Current law simply requires herbal supplements8
bearing such labeling claims to include a disclaimer that "these products
are not intended to diagnose, treat, cure, or prevent any disease." 9 But
despite the disclaimer, many people expect herbal supplements to help
what ails them, meaning that they expect a therapeutic effect.10
DSHEA fails as a regulatory system for herbal remedies. While it
safeguards access to herbal remedies, DSHEA only allows vague labeling
information suggesting the therapeutic potential of the herb." There is no
guarantee of safety or quality, and it is up to the consumer to turn to the
available literature about the herbal ingredient for guidance on how to use
the herb in a therapeutic way and to assess how effective that use is.12 In
an effort to prevent consumer confusion resulting from unapproved
therapeutic claims about herbs, the FDA has issued a final rule that
attempts to define the difference between permissible structure-function
claims and impermissible disease claims on dietary supplements. 13 This
5. See generally Steven B. Steinborn & Kyra A. Todd, The End ofPatenzalism: A New
Approach to Food Labeling, 54 FOOD & DRUG L.J. 401, 401 (1999). See also Margaret
Gilhooley, Herbal Remedies and Dietary Supplements: The Boundaries of Drug Claims and
Freedom of Choice, 49 FLA. L. REV. 663, 666 (1997). Professor Gilhooley writes that, "The
enactment of DSHEA became a harbinger of a new era of re-examination of the appropriate
limits of regulatory power." Id. Further, Gilhooley notes that "being DSHEAed" has
become a catch-phrase for deregulation. Id.
6. Kava Kava is an herbal remedy for anxiety, and has been marketed with claims
suggesting treatment for anxiety. See Sandra Salera Lloyd, Calm Yourself With Kava,
PREVENION's GuiDE: HEALING HERBS, March 2, 1999, at 81.
7. Ephedra is an herbal remedy for asthma and congestion, but it has also been marketed
for weight loss and as an herbal alternative to obtain a drug-like high. See discussion infra
p. 43.
8. The term "herbal supplement" refers to herbal remedies that are marketed as dietary
supplements. See infra note 80 and accompanying text.
9. Dietary Supplement Health and Education Act of 1994, Pub. L. No. 103-417, § 6, 108
Stat. 4325, 4329 (1994) (codified as amended in scattered sections starting at 21 U.S.C. §
301 (1994)). Section 6 provides that: "[A] statement for a dietary supplement may be made
if... the statement contains, prominently displayed and in boldface type, the following:
'This statement has not been evaluated by the Food and Drug Administration. This product
is not intended to diagnose, treat, cure, or prevent any disease'." Id.
10. See Brody, Americans Gamble, supra note 1. "[H]erbs formulated as capsules,
tinctures, extracts and teas... are now routinely used by a third of American adults seeking
to enhance their health or alleviate their illness." Id.
11. See id.
12. See id.
13. See Regulations on Statements Made for Dietary Supplements Concerning the Effect
of the Product on the Structure or Function of the Body, 65 Fed. Reg. 1000, 1000 (2000) (to
be codified at 21 C.F.R. § 101) [hereinafter Final Rule].
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rule does not improve the quality or usefulness of labeling information
consumers receive about herbal supplements. Instead, it increases
consumer confusion vis-h-vis herbal supplements. This Note argues that an
alternative system of regulation which allows herbal remedies to be
marketed as such would be better than the present regulation of herbal
remedies under DSHEA, in which herbal remedies must masquerade as
dietary supplements.'
4
Part I of this Note describes the regulatory history of herbal products
before DSHEA. Part II describes the current regulation of herbal remedies
as dietary supplements under DSHEA. In Part M, this Note assesses the
problems that arise when herbal remedies are marketed as dietary
supplements. Herbal product manufacturers are not compelled to provide
information that would allow consumers to make informed purchasing
decisions about herbal remedies as an alternative to conventional therapy
when they market herbal remedies as dietary supplements. Part ImI explains
how DSHEA transformed the way the FDA could protect public health
with respect to herbal products. Under DSHEA, the burden of proof is on
the FDA to show that an herbal supplement is unsafe or that an herbal
claim is unsubstantiated. This burden shift has resulted in a lack of
enforcement actions to protect consumers from unsafe and misleading
claims on herbal supplements. The final rule does not alleviate the safety
and effectiveness concerns for consumers who wish to use herbs as
therapy. Consequently, Part IV outlines an alternative regulatory scheme
for herbal remedies in which herbal manufacturers are compelled to
comply with herbal monographs that provide useful and reliable safety and
effectiveness information to consumers before they could make therapeutic
claims about the active, herbal ingredient in their product.
I. THE REGULATORY HISTORY OF HERBAL REMEDIES
BEFORE DSHEA
There is no specific regulatory category in the Federal Food, Drug and
Cosmetic Act (FDCA)15 for herbal remedies. The FDCA defines "food" as
"articles used for food or drink for man" and "articles used for components
14. Professor Gilhooley, who served as a member of the Commission on Dietary
Supplement Labels, states that most of the Commissioners concluded that "consumers
would be better served by clear information about the traditional therapeutic uses of
botanicals when they have scientific support, rather than by the use of DSHEA...."
Gilhooley, supra note 5, at 668. The Commission recommended the study of an alternative
regulatory system for herbal products, and Gilhooley describes two rationales for an
alternative system in her article. See id. at 668, 710-16. One rationale is grounded in the
traditional use of herbal remedies; allowing direct claims regarding the therapeutic benefits
of herbal remedies is better than the present system under DSHEA, which only allows for
vague and indirect claims regarding the therapeutic potential of herbs. See id. at 710-12.
15. 21 U.S.C. §§ 301 etseq. (1994).
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of any such article., 16 The FDCA defines "drug" as:
(A) articles recognized in the official United States Pharmacopoeia,
[and other identified compendia] ... and (B) articles intended for
use in the diagnosis, cure, mitigation; treatment, or prevention of
disease in man or other animals; and (C) articles (other than food)
intended to affect the structure or any function of the body of man
or other animals.17
Thus, the FDA may regulate as a drug any product that makes a disease
claim to treat, cure or prevent disease. 18 Further, the FDA may regulate
any product that claims to affect the structure or function of the body as a
drug unless that product is a food.19 Unlike drugs, foods can make
"structure-function" claims without FDA approval.20 Drugs can enter the
market only if they survive the FDA's "new drug approval" (NDA) process
for safety and efficacy.21 However, drugs marketed before the passage of
the first Federal Food, Drug and Cosmetic Act in 1938 that complied with
the Food and Drugs Act of 1906, and made no new labeling statements, are
exempt from the NDA process. 22 Further, drugs that are "generally
recognized ... as safe and effective for use under the conditions
prescribed" in the labeling are also exempt from the new drug approval
23process. Thus, a drug can enter the market if it complies with the
applicable over-the-counter drug monograph and meets other conditions for
over-the-counter drugs status, because this guarantees that the product is
"generally recognized as safe and effective." 24 An additional regulatory
category is "food additive," which the FDCA defines as "any substance the
intended use of which results or may reasonably be expected to result... in
its becoming a component or otherwise affecting the characteristics of any
food."2 All food additives require pre-market approval for safety by the
FDA before entering the market.
26
Before DSHEA, the FDA regulated dietary supplements as "foods,
drugs, or both."27 The marketing of herbal products as supplements started
16. 21 U.S.C. § 321(f) (1994).




21. Id. § 355(a).
22. See id. § 32 1(p)(1).
23. Id.
24. General Conditions for General Recognition as Safe, Effective and Not Misbranded,
21 C.F.R. § 330.1 (1999).
25. 21 U.S.C. § 321(s) (1994).
26. See id. § 348(c)(3)(A).
27. Regulation of Dietary Supplements; Advanced Notice of Proposed Rulemaking, 58
Fed. Reg. 33690, 33692 (1993).
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before DSHEA. Consequently, the regulatory history of dietary
supplements is also the regulatory history of herbal remedies. Before
DSHEA, the FDA used its drug authority29 and food additive authority30 to
regulate dietary supplements. 31 The effect of the FDA's use of its drug
authority was to prevent the marketing of herbal products until the requisite
pre-market approval for both safety and effectiveness was obtained.
DSHEA created the category of "dietary supplement," which explicitly
incorporates herbal products, to effectively shield that category from
regulation as a drug or food additive by making the dietary supplement
32
status equivalent to food. But even before DSHEA was enacted,
Congress and the judiciary responded to what they saw as over-regulation
by the FDA.33  DSHEA is the culmination of legislative, judicial and
lobbyist efforts34 to stop the imposition of "unreasonable regulatory
barriers limiting or slowing the flow of safe products and accurate
information to consumers. 35
Under the FDCA, the intended use of the product determines its
regulatory status.36 If the labeling of a product suggests use for treatment,
cure, mitigation or prevention of disease, or to affect the structure or
function of the body, then the FDA can take the product off the market, and
subject it to the lengthy and costly NDA process. 7 A landmark case from
the 1940s, Kordel v. United States, put the FDA in a powerful position to
use its drug authority to regulate herbal products.38 In Kordel, the United
28. See Gilhooley, supra note 5, at 676.
29. The term "drug authority"' refers to the FDA's use of the drug provisions in the
FDCA to require a substance to undergo the new drug approval process for safety and
efficacy. See id.
30. The term "food additive authority" refers to the FDA's use of the food additive
provisions of the FDCA to require premarket approval for safety. See id.
31. See id.
32- Pub. L. No. 103-417, § 3, 108 Stat. 4325, 4327 (1994) (codified as amended in
scattered sections starting at 21 U.S.C. § 301 (1994)). Section 3 provides that: "Except for
purposes of section 201(g), a dietary supplement shall be deemed to be a food within the
meaning of this Act." Id. The FDCA defines "food" as "(1) articles used for food or drink
for man or other animals, (2) chewing gum, and (3) articles used for components of any
such article." 21 U.S.C. § 321(f) (1994). Foods do not require premarket- approval by the
FDA for safety before entering the market. See id. § 342.
33. See Gilhooley, supra note 5, at 671.
34. See Statement by the President of the United States Upon Signing S. 784, 30 WEEKLY
COMP. PIuS DOC. 2158 (Oct. 31, 1994) "After several years of intense efforts,
manufacturers, experts in nutrition, and legislators, acting in conscientious alliance with
consumers at the grassroots level, have moved successfully to bring common sense to the
treatment of dietary supplements under regulation and law." Id.
35. § 2(13).
36. See 21 U.S.C. § 321(g)(1).
37. See, e.g., United States v. Vitasafe Formula M., 226 F. Supp. 266, 278 (D.N.J. 1964).
The court upheld the seizure of a vitamin and mineral product because the manufacturer's
intent, as gleaned from the product label, was that consumers use the product as a drug. See
id. Therefore, the product was a drug for purposes of regulation. See id.
38. 335 U.S. 345 (1948).
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States Supreme Court broadly defined the term labeling to embrace
statements within pamphlets mailed separately by the manufacturer to
retailers (even when the material was not physically attached to the product
itself).39 Consequently, before DSHEA, the FDA could invoke its drug
authority against herbal remedies if pamphlets and circulars accompanying
them suggested use for treatment or prevention of disease, or a use that
affects the structure or function of the body.n°
In the 1960s, the FDA took an aggressive stance towards regulating
41vitamin and mineral supplements. It relied on its drug authority as its
primary regulatory tool. It was concerned by the increased use of high
dosages of vitamins and minerals, and wanted to restrict them "to uses for
which there was a recognized nutritional need. ' 42 Consequently, the FDA
passed final regulations in 1973 that prohibited irrational combinations of
vitamins and minerals when sold as foods, and set the maximum and
minimum potency levels for nutrients.43 If a nutrient exceeded the
maximum potency level, the FDA would regulate it as an unapproved
drug.44 These regulations were challenged in court in National Nutritional
Foods Ass'n v. FDA.45 The FDA won only a "partial victory. ' 46 The court
held that the FDA could limit vitamin and mineral ingredient doses in order
to protect consumers from confusion about their therapeutic effect.47
However, the court also held that the mere fact that a nutrient is sold in
high doses will not automatically subject it to regulation as an unapproved
drug.48 In the future, the FDA would have to show more in order to
establish that a supplement manufacturer intended consumers to use its
product as a therapy.4 9 This holding made the FDA's drug authority less
effective as a regulatory weapon against dietary supplements.
Some consumers, professionals and dietary supplement manufacturers
resisted the FDA's regulatory efforts with "fervor."50  They lobbied
Congress for a legislative change,51 and their efforts paid off with the
39. Id.
40. See, e.g., id. (affirming lower court's holding that a sarsaparilla beverage composed
of a vitamin, mineral and herb combination was an unapproved new drug because printed
pamphlets and circulars that accompanied the beverage indicated that the beverage could be
used to relieve arthritis pain).
41. See Gilhooley, supra note 5, at 673.
42. See id.
43. See Definitions and Standards of Identity for Food and Special Dietary Uses, 38 Fed.
Reg. 20730, 20738 (1973).
44. See id.
45. 504 F.2d 761, 789-92 (2d Cir. 1974).
46. Gilhooley, supra note 5, at 674.
47. See National Nutritional Foods Ass'n, 504 F.2d at 789-92.
48. See id. at 789.
49. See id.
50. See Gilhooley, supra note 5, at 674.
51. See id.
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enactment of the Proxmire Amendment. This Amendment revoked the
FDA's authority to subject vitamins and minerals to regulation premised
solely on irrational combinations or high dosage.53 It also codified the
holding in National Nutritional Foods Ass'n that barred the FDA from
using its drug authority against a vitamin or mineral product "solely
because it exceeds the level of potency which [the FDA] determines is
nutritionally rational or useful."54
Before DSHEA, the FDA argued that the grandfather exemption55 for
"commonly used" food additives in existence before 1958 exempted only
those food additives present in the United States before 1958.56 The effect
was to exclude many traditional herbs used in Chinese and other cultures
from the grandfather exemption. However, the Ninth Circuit Court of
Appeals paved the way for herbal ingredients widely used outside of the
United States to fall within the grandfather exemption.57 The effect of this
decision was to impede the FDA's use of its food additive authority against
herbal supplements.58
With its drug authority and food additive authority stripped of much of
their bite, the FDA relaxed its regulatory stance against dietary
supplements. However, the FDA was forced to review its policy of scaled-
back enforcement as a result of the L-tryptophan crisis in 1993. 59 Thirty-
eight deaths and fifteen hundred adverse effects were attributed to use of L-
tryptophan as a dietary supplement to enhance body-building.60  In
response, the FDA issued an Advance Notice of Proposed Rulemaking that
requested public comment on whether to treat L-tryptophan and other
52. See id. at 675.
53. See 21 U.S.C. § 350 (1994). This section codifies the "Proxmire Amendment," the
exact language of which reads:
Except as provided in paragraph (2)-
(A) the Secretary may not establish... maximum limits on the potency of
any synthetic or natural vitamin or mineral within a food to which this
section applies;
(B) the Secretary may not classify any natural or synthetic vitamin or
mineral (or combination thereof) as a drug solely because it exceeds the




55. See 21 U.S.C. § 321(s) (1994). The grandfather exemption provides that any
"substance used in food prior to January 1, 1958, [that is recognized] through either
scientific procedures or experience based on common use in food [is deemed] to be safe
under the conditions of its intended use." Id.
56. See Fmali Herb, Inc. v. Heckler, 715 F.2d 1385, 1389-90 (9th Cir. 1983).
57. See id.
58. See Edgar R. Cataxinos, Note, Regulation of Herbal Medications in the United
States: Germany Provides a Model for Reform, 1995 UTAH L. REv. 561, 569 (1995).
59. See Gilhooley, supra note 5, at 676-77.
60. See id. at 677.
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amino acids as unapproved drugs.61 Further, the FDA invoked its food
additive authority against the current marketing of many other amino
62
acids. For many, this signaled a return to the regulatory era before the
Proxmire Amendment.63 Interest groups organized a "national blackout
day" where products at risk of being taken off the market by the FDA were
draped in black.64 The backlash by many consumers and vitamin and
herbal product manufacturers to the Advance Notice was one of the driving
forces behind the drafting and eventual adoption of DSHEA.65
Another impetus toward the enactment of DSHEA was the FDA's
interpretation of the Nutrition Labeling and Education Act of 1990
(NLEA),66 which affected herbal products.67 The NLEA authorized
conventional foods to bear certain health claims68 that met an evidentiary
standard of "significant scientific agreement," and were approved by the
FDA.69  The FDA subsequently approved four of the six legislatively
suggested health claims for conventional foods. 70 The NLEA also opened
the door for health claims describing a relationship between dietary
71supplements (including herbs) and disease. It left it up to the FDA's
discretion whether or not to adopt a lower standard of scientific proof for
approval of such claims on dietary supplements.72 The FDA chose to
require herbal product manufacturers also to meet the "significant scientific
agreement" standard in order to make health claims.73  Consequently,
61. See Regulation of Dietary Supplements; Advanced Notice of Proposed Rulemaking,
58 Fed. Reg. 33690, 33697 (1993).
62. See Regulation of Dietary Supplements; Advanced Notice of Proposed Rulemaking,
58 Fed. Reg. at 33696.
63. See Gilhooley, supra note 5, at 678.
64. ScoTT BASS & ANTHONYL. YOUNG, DIETARY SUPPLEMENT HEALTH AND EDUCATION
ACT: A LEGISLATIVE HISTORY AND ANALYSIS 297, 300 (1996).
65. See Gilhooley, supra note 5, at 678.
66. Pub. L. No. 101-535, 104 Stat. 2353 (1990) (codified as amended at 21 U.S.C. §§
301, 321, 337, 343, 345, 371 (1994)).
67. See Gilhooley, supra note 5, at 678.
68. A food-disease health claim describes the relationship between a particular food and
disease or a health-related condition. 21 U.S.C. § 343(r)(1)(B) (1994).
69. Id. § 343(r)(3)(B)(i). "The Secretary shall promulgate regulations authorizing
[health] claims... [when] there is significant scientific agreement, among experts qualified
by scientific training and experience to evaluate such claims, that the claim is supported by
such evidence." Id.
70. The NLEA required the FDA to evaluate six food-disease health claims describing
the relationship between calcium and osteoporosis, dietary fiber and cancer, lipids and
cancer, lipids and cardiovascular disease, dietary fiber and cardiovascular disease, and
sodium and hypertension. See Nutrition Labeling and Education Act of 1990 §
3(b)(1)(A)(vi), 104 Stat. 2353, 2361 (1990). Applying the "significant scientific agreement"
standard, the FDA approved the claims linking calcium and osteoporosis, saturated fats and
both cholesterol and cardiovascular disease, dietary lipids and cancer, and sodium and high
blood pressure. See 21 C.F.R. §§ 101.72-101.76 (1999).
71. See Nutrition Labeling and Education Act of 1990 § 3(b)(1)(A)(x).
72. See id.
73. See Health claims: general requirements, 21 C.F.R. §§ 101.14(a)(1), 101.13(c)
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because of the high level of proof necessary to meet the "significant
scientific agreement" standard, the FDA declined to approve any of the
four suggested health claims for dietary supplements. 74
By 1993, herbal product manufacturers and pro-herbal product
consumers faced a precarious situation. The period of scaled-back
enforcement of FDA regulatory provisions against dietary (including
herbal) supplements during the 1970s and 1980s seemed to be over.
Because of the FDA's decision to treat health claims for dietary
supplements and food alike, the NLEA proved disappointing as a means of
disseminating information about the health benefits of dietary supplements.
Further, it appeared that the FDA would not hesitate to use its drug and
food additive authority against suspect dietary supplements like L-
tryptophan. Yet the consumer demand for access to herbal, vitamin and
mineral supplements and information about them was high. Further,
supplement manufacturers had a vested interest in keeping the market open
for their products. The time was ripe for legislative reform.
II. THE CURRENT REGULATION OF HERBAL REMEDIES AS
DIETARY SUPPLEMENTS
DSHEA was Congress' acceptance of the notion that a healthful diet
can "mitigate the need for expensive medical procedures,"75 be
"preventive ' 76 and "promote good health" and "longevity. 77  DSHEA
implemented Congress' belief that "consumers should be empowered to
make choices about preventive health care programs based on data from
scientific studies of health benefits related to particular dietary
supplements." 78 One of the goals of DSHEA was to decrease the overall
cost of healthcare in the United States by curbing unreasonable regulatory
barriers that limit the availability of dietary supplements and dissemination
79
of truthful information to consumers.
(1999).
74. The FDA rejected health claims linking dietary fiber and cancer, antioxidant vitamins
and cancer, omega-3 fatty acids and heart disease, and zinc and immune function in the
elderly. See Health Claims; Not Authorized, 21 C.F.R. § 101.71 (1999).
75. Pub. L. No. 103-417, §2(4), 108 Stat. 4325, 4326 (1994) (codified as amended in
scattered sections starting at 21 U.S.C. § 301 (1994)). "Congressional finding: "[H]ealthful
diets may mitigate the need for expensive medical procedures, such as coronary bypass
surgery or angioplasy." Id.
76. Id. §2(5). Congressional finding: "[P]reventive health measures, including education,
good nutrition, and appropriate use of safe nutritional supplements will limit the incidence
of chronic diseases, and reduce long-term health care expenditures." Id.
77. Id. §2(6)(A). Congressional finding: "[P]romotion of good health and healthy
lifestyles improves and extends lives while reducing health care expenditures." Id.
78. Id. §2(8) (exact language of Congressional finding appears in the text).
79. Id. §2(13) Congressional finding: "[A]Ithough the Federal Government should take
swift action against products that are unsafe or adulterated, the Federal Government should
not take any actions to impose unreasonable regulatory barriers limiting or slowing the flow
of safe products and information to consumers." Id.
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DSHEA provides a convenient regulatory vehicle-i.e., dietary
supplements-for herbal remedies to enter the market. A dietary
supplement is defined as:
(1) [A] product (other than tobacco) intended to supplement the
diet that bears or contains one or more of the following dietary
ingredients: (A) a vitamin; (B) a mineral; (C) an herb or other
botanical; (D) an amino acid; (E) a dietary substance for use by
man to supplement the diet by increasing the total dietary
intake... [and] (2)(A)(i) is intended for ingestion... [and] (2)(C)
is labeled as a dietary supplement.80
Previously, herbal remedies, which at the least promise to affect the
structure or function of the body, could only enter the market if they
survived the NDA process. 8' Consequently, it was very difficult for herbal
products to enter the market. 82 The cost and strict evidentiary standard
necessary to meet the safety and effectiveness requirement of the NDA
process are preclusive. Since herbs are natural botanicals, it is very
difficult for herbal product manufacturers to patent their products in order
to protect a reasonable rate of return on the cost of the research and testing
necessary to obtain FDA approval as a new drug.84 Further, the FDA's bias
in favor of single-active ingredient drugs for over the counter drugs (OTC)
status85 and its reluctance to incorporate foreign marketing experience into
the OTC evaluative process is also preclusive.
86
DSHEA creates a safe niche in the market for herbal remedies as
87dietary supplements. Firstly, any herbal product that meets the definition
of a dietary supplement is exempt from classification as a food additive.
88
80. §3(a).
81. See supra notes 17-21 and accompanying text.
82. See Cataxinos, supra note 58, at 574. NDA costs an average of $50 to S100 million
per product. See id. The cost, coupled with the fact that it is extremely difficult for herbal
manufacturers to obtain a patent for their products, means that there is little incentive to put
herbal remedies through the NDA process. See id.
83. See id. See also Scott Martin, Note, Unlabelled "Drugs" as U.S. Health Policy: The
Case for Allowing Health Claims on Medicinal Herb Labels; Canada Provides a Model for
Reform, 9 ARIZ. J. INT'L & COMP. L. 545, 552 (1992).
84. See THE KEYSTONE CENTER, THE FINAL REPORT OF THE KEYSTONE NATIONAL POLICY
DIALoGUE ON FOOD, NUTRmON, AND HEALTH 81 (1996).
85. See Martin, supra note 83, at 554.
86. See Robert G. Pinco, Implications of FDA's Proposal to Include Foreign Marketing
Experience in the Over-the-Counter Drug Review Process, 53 FOOD & DRUG L.J. 105, 106
(1998). Pinco states, "As a result of FDA's unwillingness to include foreign marketing
history, U.S. consumers are denied access to safe and effective ingredients that have been
used extensively throughout the world." Id.
87. See Gilhooley, supra note 5, at 670.
88. See Dietary Supplement Health and Education Act of 1994, Pub. L. No. 103-417,
§3(b), 108 Stat. 4325, 4327-28 (1994) (codified as amended at 21 U.S.C. §321s(4)-(6)
(1994)). Section 3(b) amends the FDCA to provide for the exclusion of dietary supplements
from the definition of food additive. See id.
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The effect of this is to stop the FDA from using its food additive authority89
to force supplement manufacturers to meet the premarket approval standard
for safety. DSHEA also creates a statutory presumption that all dietary
supplements are safe.90 The burden of proof is on the FDA to show that a
dietary supplement "presents a significant or unreasonable risk of illness or
injury" under recommended, or ordinary, conditions of use before it can
prevail in a court action against a supplement manufacturer to pull its
product off the market.9' In effect, dietary supplements have the same
92
regulatory status as foods.
An additional advantage of DSHEA is that it allows herbal product
manufacturers to make certain informational claims about their products.
The goal is to encourage informed decision-making by consumers about
their health. 93 There are two major provisions in DSHEA that facilitate the
dissemination of information about the health benefits of herbs. Section 6
of DSHEA authorizes supplement manufacturers to make statements of
nutritional support.94 It provides that a statement for a dietary supplement
may be made if-
[T]he statement claims a benefit related to a classical nutrient
deficiency disease and discloses the prevalence of such disease in
the United States, describes the role of a nutrient or dietary
ingredient intended to affect the structure or function in humans,
characterizes the documented mechanism by which a nutrient or
dietary ingredient acts to maintain such structure or function
[hereinafter structure-function claims], or describes general well-
being from consumption of a nutrient or dietary ingredient.95
Before DSHEA, any of these claims would have subjected herbal
products to the FDA's drug authority.96 For example, the herb Valerian is
marketed as a dietary supplement.97 For centuries, herbalists have used
98Valerian to treat panic attacks, stress and insomnia. DSHEA does not
89. See Gilhooley, supra note 5, at 701-02.
90. See Dietary Supplement Health and Education Act §§ 3,4.
91. See id. § 4. The language of section 4 reads: "In any proceeding under the
subparagraph, the United States shall bear the burden of proof on each element to show that
a dietary supplement is adulterated. The court shall decide any issue under this paragraph
on a de novo basis." Id.
92. See id.
93. See id. § 2(8).
94. See id. at § 6.
95. Id.
96. See generally Robert G. Pinco & Paul D. Rubin, Ambiguities of the Dietary
Supplement Health and Education Act, 51 FOOD & DRUG L.J. 383, 392-93 (1996)
(describing the FDA's effort to challenge certain dietary supplements, which are also
covered by OTC drug monographs, as unauthorized drugs).
97. See Brody, Americans Gamble, supra note 1 (showing illustration of a bottle of
Valerian as an example of an herbal remedy marketed as a dietary supplement).
98. See JIM O'BRiEN, HERBAL CURES FOR COMMON AILMENTS 75 (1998).
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allow manufacturers of Valerian to claim that its product is an herbal
therapy for insomnia.99 However, it does allow them to make the structure-
function claim that Valerian nutritionally promotes restful sleep.100 Under
DSHEA, these claims are statutorily permissible so long as the product
bears the required disclaimer that, "[t]his statement has not been evaluated
by the Food and Drug Administration. This product is not intended to
diagnose, treat, cure, or prevent any disease." 101 Further, the claims must
be substantiated102 and cannot be misleading. 103
DSHEA further promotes the dissemination of information about
herbal remedies through its dietary supplement labeling exemptions." 4 As
discussed previously, before DSHEA, the FDA could use statements in
publications connected with the sale of herbs to build a case that herbal
products were really unapproved new drugs.1°5 Now certain publications
connected with the sale of supplements are exempt from classification as
labeling. 106 Publications that inform consumers about the therapeutic use
of herbs are exempt from the status of labeling so long as they meet the
following requirements: they are physically separate from the herbal
supplements, do not promote a particular manufacturer or brand, present a
balanced view of the available scientific information on a dietary
supplement and are not false or misleading. 0 7 Further, the FDA has the
burden of proof to show that the publication fails to meet one or more of
the requirements for the exemption.108 The labeling exemption permits the
dissemination of information about the "off-label," therapeutic potential of
99. See Pinco & Rubin, supra note 96, at 392-93.
100. See id.
101. Dietary Supplement Health and Education Act of 1994, Pub. L. No. 103-417, § 6, 108
Stat. 4325, 4329 (1994) (codified as amended in scattered sections starting at 21 U.S.C. §
301 (1994)).
102. See id. Section 6 allows certain statements for dietary supplements provided that,
"the manufacturer of the dietary supplement has substantiation that such statement is
truthful and not misleading, .. ." Id.
103. See id.
104. See Pinco & Rubin, supra note 96, at 385-86.
105. See supra notes 38-40 and accompanying text.
106. See Dietary Supplement Health and Education Act §5.
107. See id. The exact language of section 5 exempts a publication from classification as
labeling provided that it:
(1) is not false or misleading;
(2) does not promote a particular manufacturer or brand of dietary
supplement;
(3) is displayed or presented, or is displayed or presented with other such
items on the same subject matte, so as to present a balanced view of the
available scientific information on the dietary supplement;
(4) if displayed in an establishment, is physically separate from the dietary
supplements; and






herbs to consumers, and consequently encourages the use of herbal
supplements as therapies.1°9
It is unclear what is left of the FDA's drug authority over herbal
products that contain structure-function claims. 110  Some DSHEA
authorized claims are arguably drug claims-i.e., claims of treatment,
prevention or cure.' Because many allowable DSHEA claims are
virtually indistinguishable from drug claims, they implicate the same
concerns that new drug claims pose for the consumer and the government
despite the disclaimer which instructs consumers not to rely on the product
as an FDA approved drug.112 The consumer has an interest, or concern, in
the assurance of safe and effective health products. 13 The government has
an interest in protecting consumers from fraud and safeguarding public
health by making sure that only health products that are both safe and
effective reach the consumer. 14  DSHEA, however, promotes the
consumer's countervailing interest in access to herbal products and the
information necessary to exercise their freedom to make health choices.
The next section will examine the safety and effectiveness issues that arise
when herbal remedies are marketed as dietary supplements.
III. THE PROBLEMS WITH REGULATING HERBAL
REMEDIES AS DIETARY SUPPLEMENTS
For consumers who wish to use herbs to treat or mitigate ailments,
DSHEA fails as a regulatory scheme. The consumer who wants to use a
traditional herbal therapy for depression, anxiety or to lower cholesterol is
forced to "gamble" when choosing to use an herbal supplement as a
therapy. 115 Under DSHEA, the product label may bear claims suggesting
its therapeutic potential. But the required disclaimer tells consumers to be
skeptical of the claim. Further, the consumer has no way to assess the
effectiveness or safety of the herbal remedy, and no warnings about contra-
indications, side-effects, etc.116 Consequently, for consumers who wish to
use herbal supplements as therapies for illnesses, DSHEA raises significant
safety and effectiveness concerns. These concerns are compounded by the
inadequate enforcement of the DSHEA provisions for: safety, balanced
109. See Gilhooley, supra note 5, at 696.
110. See Pinco & Rubin, supra note 96, at 388.
111. See Gilhooley, supra note 5, at 708.
112. See generally Sean Harmon, Comment, Melatonin Mania: Can the FDA Regulate
Hormonal Dietary Supplements to Protect Consumer Interests in Light of the Dietary
Supplement Health and Education Act of 1994?, 22 U. DAYTON L. REv. 77, 91-94 (1996).
113. See id. at 94.
114. See id. at 92.
115. See Brody, Americans Gamble, supra note 1.
116. See id. Brody notes that because herbal remedies are classified as dietary
supplements, they face none of the premarket hurdles of drugs for safety and effectiveness.
See id. She then comments, "Thus, countless consumers are wasting their money on useless
products or jeopardizing their health on hazardous ones." Id.
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information, the prevention of fraud and the substantiation requirement to
verify nutritional support claims.1 7  This climate of inadequate
enforcement is a result of resource constraints, n 8 which can be attributed,
in part, by the shift in the burden of proof that DSHEA created."'
To borrow from Jane E. Brody, a health and nutrition columnist for the
New York Times, DSHEA has let "chaos" reign in the market.J20 Chinese
as well as other cultures have used herbs as medicine for centuries.12 The
traditional use of many herbs is highly probative of safety 122 and suggestive
of effectiveness. It is reasonable to assume that the traditional use and
preparation of herbs resulted from a process of trial and error, which
eliminated unsafe and less effective preparations and uses. Likewise, the
existence of a product on the market for a substantial period of time is also
probative of safety' 23 as well as indicative of effectiveness for analogous
117. See FOOD AND DRUG ADMINISTRATION & CENTER FOR FOOD SAFETY AND APPLIED
NUTRITION, DIETARY SUPPLEMENT STAKEHOLDER MEETING (June 8, 1999) (visited Feb. 27,
2000) <http:/vm.cfsan.fda.gov/-dms/ds-0699.html> (statement of Annette Dickinson,
Council for Responsible Nutrition). At a public meeting sponsored by the FDA and the
Center for Food Safety and Applied Nutrition, Annette Dickinson stated:
FDA indicates that the two primary objectives for its dietary supplement
strategy are to assure consumers of safe dietary supplements, and to assure
consumers that labeling is truthful and not misleading. We fully support
these two objectives, but we would urge FDA to add a third overall objective
to this plan, and that is to fully implement DSHEA.
FDA may currently be of the opinion that this is implicit in its strategy,
but we believe it needs to be made explicit and, in fact, we believe the most
critical issue facing FDA and the industry today is the perceived failure to
implement DSHEA, which leads to the inappropriate conclusion that FDA
lacks authority to regulate these products when, in fact, the issue-as has
been mentioned already-is more enforcement and implementation.
Id.
118. See id. (statement of Jim Prochnow, lawyer for the dietary supplement industry). At
the same public meeting Mr. Prochnow stated:
[M]y biggest comment-is this: the FDA has good folks that are sitting here,
but they probably aren't going to get much [more] funding than they have
now to carry out their duties. So I hear all of these people saying a lot of
good things about what these good folks should do, but the fact of the matter
is they're going to be able to do very little more than they're doing now
without a lot of increased Federal funding, and that's unlikely to happen in
today's political atmosphere-and in the atmosphere of the dietary
supplement industry.
Id. See also Kenneth Howe, FDA Stops Tracking Herbal Remedies: Agency Says It Doesn't
Have the Funding to Assess Adverse Reactions, S.F. CHRON., Feb. 14, 2000, at Al.
119. See generally 1 JAMEs T. O'REILLY, FOOD AND DRUG ADMINISTRATION § 10.15 (2d
ed. 1995) (describing how the shift in the burden of proof creates regulatory obstacles for
the FDA).
120. See Brody, Americans Gamble, supra note 1.
121. See, e.g., O'BRiEN, supra note 98, at 89 "The Chinese have been using [ginseng] for
5,000 years." Id.
122. See Martin, supra note 83, at 572.
123. See generally Pinco, supra note 86, at 107 (discussing requirement of use for a
material extent or time in the market in order to be exempt from the NDA process; the
implicit assumption is that presence in the market for a material extent or time is probative
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reasons. DSHEA creates a market, however, in which manufacturers
experiment with the traditional herbs they market.1 4 They combine them
with other herbs to make new, non-traditional products, use non-
traditional but more cost-effective preparation techniques,126 promote
traditional herbs for non-traditional purposes 127 and put them in a more
consumer-friendly yet non-traditional form.128  This experimentation
eliminates whatever safeguards and level of effectiveness traditional use
offers.
The quintessential example of this is Global World Media
Corporation's marketing of the herb ephedra as Herbal Ecstasy.
29
Ephedra, or Ma Huang as it is known in Chinese herbal medicine, was
traditionally used as a decongestant for colds, asthma and hay fever.130 The
FDA approved ephedrine for use in cold medicine.131  Herbal ephedra
contains ephedrine, which is a compound that boosts metabolism and
thereby bums calories. 132 Ephedrine is a stimulant that can act on the body
like the illegal drug methamphetamine, which is more commonly known as
speed. 33 In the 1990's, ephedra products were marketed for weight control
purposes and also to provide an energy boost.134 A dangerous side-effect of
ephedra products is that they can speed up your heart rate, increase your
of safety).
124. See, e.g., Medicinal Herb Patents Proliferate Thanks to New Legislation,
PSYCHIATRIC TIMES, Jan. 1999, at 19, 19. The patent office issued a patent for the
combination of St. John's Wort and ephedrine as a way to curb appetite and bum calories.
See id. St. John's Wort is traditionally used alone as a therapy for mild depression. See
O'BREN, supra note 98, at 27. Further, ephedrine-a component of the herb ephedra-is
traditionally used as a decongestant. Id. at 96.
125. See generally Varro E. Tyler, Get the Best Herbal Medicine: Golden Rules to Guide
You Safely Through the Herb Aisles, PREVENTON'S GUIDE: HEALING HERBS, March 2, 1999,
at 18, 18 (recommending single-herb products as the best herbal medicines).
126. See, e.g., Jane E. Brody, 'Natural, Drug-Free' Herb May Have Risks of Its Own,
N.Y. TIMES, Feb. 9, 1999, at D6 [hereinafter Brody, 'Natural, Drug, Free']. A study of 64
'pure' ginseng products found that 60 percent of them were so watered down with cheaper
herbs as to be worthless. Id.
127. See, e.g., O'BRIEN, supra note 98, at 96. Ephedra is traditionally used as a
decongestant, but has been marketed as a diet aid and energy booster. See id.
128. See generally Tyler, supra note 125, at 15-16 (recommending that the form the herbal
product takes-i.e., tincture, capsule, or tea-should be considered when the consumer
makes his/her purchase; if the consumer intends to use the product as a traditional therapy,
then the form of the herbal product matters).
129. State Enforcement Reports; Deceptive Advertising (NAAG, Consumer Protection
Reports, Washington, D.C.), October/November 1997, at 1.
130. See O'BREN, supra note 98, at 96.
131. See Paul D. Rheingold, Herbal Supplements May Be Dangerous: Supplements May
Look Like Magic Bullets for Health Problems, But Users May Be Playing Russian Roulette,
TRMAL, Nov. 1999, at 42, 45.
132. See All-Natural Dieting Don'ts, PREVENTION'S GUIDE: HEALING HERBS, Mar. 2, 1999,
at 90.
133. See FDA Says Use of "Legal Highs" is Dangerous, N.Y. TIMES, Apr. 11, 1996, at
A22.
134. See All-Natural Dieting Don'ts, supra note 132.
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blood pressure, and trigger a heart attack. 135  Under DSHEA, however,
ephedra supplements do not have to contain directions for use and
contraindications on their labels, or any other information about side-
effects. 136 Further, there is no guarantee that the ephedra product actually
contains the quantity of ephedra specified on the label, or that the ephedra
contained in the product was extracted from the part of the plant traditional
use requires for effectiveness. 137  Consequently, it is difficult for the
consumer who wants to use ephedra for a traditional purpose (i.e., as a
decongestant or for asthma) to decide whether it is safe for him/her to do
so, and to discern which ephedra product contains the correct amount and
extract-source of the herb for safe, traditional and therapeutic use.
138
Complicating safety and effectiveness concerns is the fact that DSHEA
allows ephedra product manufacturers to imply both non-traditional and
traditional therapeutic uses through structure-function claims, which are
essentially drug claims, without premarket approval.139 Herbal remedies
like ephedra, whose claimed effects mimic the effects of regulated drugs,
pose a special public health threat because of their de-regulated marketing
status as dietary supplements. 140 Herbal supplements are seen by
consumers as safe because of the "natural equals safe" myth.14 ' As
DSHEA is currently implemented, there are not enough federal safeguards
to prevent the consumer from abusing herbal remedies like ephedra.142
135. See id.
136. See generally Brody, 'Natural, Drug-Free,' supra note 126.
137. See Dietary Supplement Health and Education Act of 1994, Pub. L. No. 103-417, § 7,
108 Stat. 4325, 4329-31 (1994) (codified as amended in scattered sections starting at 21
U.S.C. § 301 (1994)). DSHEA requires herbal supplement manufacturers to name each
ingredient, its quantity, and the part of the plant from which the herb is derived. See id.
However, it only requires the disclosure of the daily percentage value (DV) of those
ingredients for which the DV has been established. See id. No DV has been established for
herbs. See Harmon, supra note 98, at 90-91. Thus, consumers have no way of assessing
from the label whether the herbal product they are taking has enough (or too much) of the
active herbal ingredient they want for therapeutic use; whether the herb was extracted from
the part of the plant required for traditional, therapeutic use; or, what kind of a risk they are
taking when they use the herbal product. See generally id.
138. See Gina Kolata, Drug or Food? Patients Stumble into Gray Area, N.Y. TIMEs, Feb.
9, 1999, at D6. Kolata explains that because a substance sold as a supplement is not
regulated by the FDA, there is no guarantee that it will contain the product on its label or
that the dosage stated on the label is accurate. See id.
139. See supra notes 111-114 and accompanying text.
140. See Harmon supra note 112, at 91-94.
141. See Stephen Barrett, The Herbal Minefield (visited March 1, 1999)
<http://www.quackwatch.com/OlQuackeryRelatedTopics/herbs.html>. Dr. Varro E. Tyler,
Dean Emeritus of the Purdue University School of Pharmacy and Pharmacal Sciences,
explains, "Particularly insidious is the myth that there is something almost magic about
herbal drugs that prevents them, in their natural state, from harming people." I.
142. The regulatory history of ephedra, itself, serves as an example. The FDA began
opposing the use of ephedra in 1997. See Rheingold, supra note 131, at 43. It held hearings
and issued proposed regulations for labeling ephedrine alkaloids. See id. Hox ever, no final
regulations are in place to protect consumers. See id.
Consequently, because of how DSHEA is currently implemented, 43 tort
actions which can result in herbal manufacturers being required to place
warnings on their labels, 144 and the ability of states to exercise their police
power against dangerous herbal remedies, 145 seem to be the only real
avenues left to prevent the abuse of herbal remedies like ephedra.
146
Global World Media Corporation pushed DSHEA to its limits with the
claims that it made. 147 The label for its ephedra product, Herbal Ecstasy,
contained claims that implied such effects as "euphoria, increased sexual
sensations, heightened awareness, increased energy, and other effects.' 48
The implied narcotic-like drug claims combined with the false but popular
notion that "natural equals safe" proved to be a recipe for danger. 149 Since
nothing in the label warned consumers about the dangers of ephedra,
consumers in pursuit of a high felt safe in going beyond the recommended
dosage.150  It was natural for those consumers to think that the more
ephedra they took the better the high they would get.151 At least thirty-
eight deaths have been associated with the use of ephedra products.
152
It took the FDA four years, and more than one hundred reports of life-
threatening symptoms and thirty-eight deaths, to act against ephedra.153 It
is important to assess the cause of the FDA's delay in responding to the
143. See Higgins, supra note 3, at 62-63. Higgins describes how the availability of limited
resources by the FDA forces it to pursue only those herbal supplements that have been
shown to cause direct harm to consumers. See id. at 62. Products with unsubstantiated
labeling claims (or those which may indirectly pose a significant or unreasonable risk) are a
"much smaller priority." Id. As Robert Moore, a senior regulatory scientist at the FDA's
Office of Special Nutritionals, stated, "We can always challenge substantiation of claims.
It's simply a matter of where it fits in the priorities scheme." Id.
144. See Rheingold, supra note 131, at 45. Rheingold further describes how plaintiffs'
lawyers can raise various impurity claims against herbal supplement manufacturers, and also
advocates "nutritional malpractice" claims against nutritionist, diet advisers, trainers, etc.
Id.
145. See, e.g., State Enforcement Reports; Deceptive Advertising (NAAG, Consumer
Protection Reports, Washington, D.C.), October/November 1997, at 1. (describing how
several states' attorneys general initiated action against Herbal Ecstasy).
146. See generally COMMISSION REPORT, supra note 4, at 24-26.
147. See Peter A. Vignuolo, Note, The Herbal Street Drug Crisis: An Examination of the
Dietary Supplement Health and Education Act of 1994, 21 SETON HALL LEGIS. J. 200, 205
n.28 (1997).
148. See Dietary Supplements Containing Ephedrine Alkaloids, 62 Federal Register
30.678, 30.1679 (1997) (to be codified at 21 C.F.R. § 111) (proposed June 4, 1997).
149. See generally Brody, Americans Gamble, supra note 1 (discussing how the herbal
realm wins new converts in part because of the "natural" equals "good" belief; also
discusses the availability of products listed in European and American authorities as
ineffective, unsafe, or both).
150. See, e.g., Vignuolo, supra note 147, at 200 (describing the case of Peter Schlendorf, a
twenty-year old college student who died from an overdose of a dietary supplement
containing ephedra; he had taken eight pills even though the recommended dosage was four;
the friends he was with at the time had taken twelve).
151. See id.
152. See Brody, Americans Gamble, supra note 1.
153. See id.
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ephedra crisis. 154  Some have suggested that the delay was-either
consciously or unconsciously-politically motivated to encourage
Congress to enact more restrictive dietary supplement legislation.
155
However, DSHEA transformed the means by which the FDA protects
public health and acts against consumer fraud with respect to herbal
supplements. The practical restraints of time and money that increased as a
result of the regulatory change DSHEA enacted probably best accounts for
the FDA's delay. DSHEA, as well as regulation in the post-DSHEA era in
general, forces the FDA to use methods that increase consumer awareness
of safety and effectiveness concerns as its default method of regulation,
instead of banning a product from the market and subjecting it to lengthy
and costly testing.156  The effect is to move away from a paternalistic
regulatory regime towards a regime that promotes consumer choice with
respect to health decisions while meeting safety and effectiveness concerns
by the disclosure of relevant information. 157
As Professor Margaret Gilhooley explains, DSHEA replaces the
premarket approval model for safety with a court-enforcement and
substantiation model. 158 Consequently, there is a shift in the burden of
proof.' 59 The FDA must show either that old herbal supplements (i.e.,
those present in the market before 1994) pose a "significant or
unreasonable risk" of injury' 60 or new herbal supplements fail to meet the
substantiation requirement for safety before it can bring a court
enforcement action against an herbal supplement manufacturer.' 6' The
shift in the burden of proof poses a huge administrative burden on the
FDA. 62 It forces the FDA to make tough resource allocation decisions,
which in the context of dietary supplements has meant that the supplement
industry can market its products without any real threat of enforcement
supervision.
163
Still, there are regulatory paths available under DSHEA that the FDA
has not currently taken. For example, it is within the FDA's authority to
154. See generally Gilhooley, supra note 5, at 704-05 (discussing ways in %Nhich the FDA
can adequately work under the DSHEA regime to meet safety and effectiveness concerns).
155. See Pinco & Rubin, supra note 96, at 398.
156. See, e.g., Pearson v. Shalala, 164 F.3d 650, 656 (D.C. Cir. 1999), rch'g en banc
denied, 172 F.3d 72 (D.C. Cir. 1999) (per curiam).
157. See Steinborn & Todd, supra note 5, at 401-02.
158. See Gilhooley, supra note 5, at 705.
159. See Dietary Supplement Health and Education Act of 1994, Pub. L. No. 103-417, § 4,




162. See Gilhooley, supra note 5, at 705.
163. See generally id. ("When the agency can only take enforcement action in court, the
less responsible members of the industry do not have the same concern with being sure that
the agency can bring enforcement action when needed.").
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require old herbal supplements to bear the warning that the FDA has not
evaluated the safety of the product in order to prevent consumer
deception.164 This is consistent with the goals of DSHEA to preserve
consumer access to herbal supplements, 165 and its preference for regulation
in the form of increased labeling requirements in order to promote the
dissemination of truthful information about herbal remedies rather than
subjecting them to premarket approval process. 166
Acting to increase warnings in labeling is also consistent with current
case law. 167 In Pearson v. Shalala, the D.C. Circuit held that the FDA
cannot prohibit the marketing of dietary supplements with health claims
when evidence, albeit inconclusive evidence, exists to support that claim.
168
Instead, it should use disclaimers to cure those "misleading" health
claims.1 69  Otherwise, the FDA is violating the commercial speech
doctrine. 17 Lastly, a warning requirement has the added policy benefit of
providing an incentive for manufacturers of old herbal supplements to
voluntarily provide the FDA with evidence substantiating safety so as to
avoid the need for a warning.
171
With respect to new herbal supplements, the FDA has the rulemaking
authority to require manufacturers to provide access to files needed to
determine whether the substantiation requirement for safety has been
met. 72 This is consistent with the mandate of the FDA to safeguard public
health, and consistent with the goal of DSHEA to make the de-regulation
of dietary supplements safe by assisting with the dissemination of truthful
information about those supplements. 174 Lastly, the FDA can help
consumers make informed decisions about the herbal remedies they buy, by
actively making sure that publications about herbal supplements meet the
requirements for the labeling exemption. 175 For example, the FDA should
actively enforce the exemption requirement which provides that only
164. See Gilhooley, supra note 5, at 703.
165. See Dietary Supplement Health and Education Act of 1994, Pub. L. No. 103-417, § 4,
108 Stat. 4325, 4328 (1994) (codified as amended in scattered sections starting at 21 U.S.C.
§ 301 (1994)).
166. See id. at § 2(8).




171. See Gilhooley, supra note 5, at 705.
172. See id. at 704. See also Food Labeling; Nutrient Claims and Health Claims; Special
Requirements, 61 Fed. Reg. 3884 (1996) (to be codified at 21 C.F.R. § 101) (proposed Feb.
2, 1996) (proposing rule to require manufacturers to provide access to files needed to assess
substantiation for safety and nutritional support claims).
173. See Harmon, supra note 112, at 92.
174. See Dietary Supplement Health and Education Act of 1994, Pub. L. No. 103-417, §
2(8), 108 Stat. 4325, 4326 (1994) (codified as amended in scattered sections starting at 21
U.S.C. § 301 (1994)).
175. See Gilhooley, supra note 5, at 697-700.
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publications presenting a "balanced view" are eligible. 176 A balanced view
that honestly discloses how safe and effective an herb is currently known to
be encourages the informed use of herbal remedies. As Professor
Gilhooley suggests, the FDA could allow publications presenting an
unbalanced view in retail stores; however, it should require a disclaimer on
the publication that it makes no effort to promote a balanced view. 177 This
would discourage such publications while enabling the consumer interested
in using herbs as therapy to better assess the safety and effectiveness of
different herbs. Aggressive enforcement of the balanced view requirement
by the FDA would also provide a research incentive on the part of herbal
manufacturers to sponsor scientific studies in an effort to establish
favorable data on their products.
Further, the FDA should actively enforce the exemption requirements
proscribing the promotion of a particular manufacturer or brand, and
requiring that publication displays be physically separate from the
178
supplements. This would ensure safety by eliminating the false
impression that the brand advertised or available in the retail store meets
the recommendations in the publication for the best herbal product or
therapeutic use of an herb.
Instead of actively making sure that herbal manufacturers are adhering
to DSHEA provisions like the substantiation requirement and the
publication exemption requirements, however, the FDA has issued a final
rule that more clearly defines the difference between disease claims and
structure-function claims. 179 Using this rule, if the FDA found that an
herbal supplement manufacturer was making a disease claim (even though
the manufacturer thought it was only making a structure-function claim), it
could invoke its drug authority against the product. 180 This harkens back to
the Pre-Proxmire Amendment days when the FDA sought to regulate
megavitamins as drugs to prevent the "irrational" use of vitamins by
consumers."' Similarly, with the final rule, the FDA seems to want to
prevent the "irrational" use of herbs as therapies by limiting the type of
claims herbal supplement manufacturers can make. The following section
will evaluate the final rule and argue that Congress should amend the
FDCA to create a new category of products called traditional herbal
therapies. Allowing herbal manufacturers to finally market their products
as traditional herbal therapies is in the best interests of the consumer who
wishes to use herbs as therapy.
176. See id. at 699-700.
177. See id. at 700.
178. See id. at 697-98.
179. See Final Rule, supra note 13, at 1000.
180. See id. at 1010-11.
181. See supra notes 28-36 and accompanying text.
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IV. AN ALTERNATIVE REGULATORY SCHEME FOR
HERBAL REMEDIES
The FDA issued a final rule on dietary supplements on January 6,
2000.182 This rule limits the ability of herbal supplement manufacturers to
imply drug claims, or claims which assert that a product can mitigate,
prevent, or treat a disease, via structure-function claims. 183 The goal is to
prevent consumers from "substitut[ing] potentially ineffective products for
proven ones, foregoing or delaying effective treatment for serious and life-
threatening illnesses."'184 It is questionable whether the final rule is
consistent with the underlying purposes of DSHEA 85 and the current trend
in the case law to prefer the use of disclaimers rather than the outright
proscription of certain claims on dietary supplements. 186 Additionally, the
effect of this rule is to add to the confusion of consumers who wish to use
herbal supplements as therapies. 87 It will further impede their ability to
discern from a product label what the health benefits are in terms of the
treatment of illnesses or disease. 188 An alternative system of regulation that
allows herbal therapies to be marketed as such would be better than the
current system under DSHEA in which herbal therapies must masquerade
as dietary supplements. 189 The current difficulty the FDA is experiencing
in trying to define the line between permissible and impermissible
structure-function claims lends further support for an alternative system of
182. See Final Rule, supra note 13.
183. See id. at 1012.
184. See id. at 1001.
185. The final rule treats express disease claims and implied disease claims the same. See
Final Rule, supra note 13, at 1012. Most of the comments in response to the proposed
version of this rule argued that Congress intended to allow implied disease claims under
DSHEA. See Regulations on Statements Made for Dietary Supplements Concerning the
Effect of the Product on the Structure or Function of the Body; Public Meeting, 64 Fed.
Reg. 36824, 36825 (July 8, 1999). Three sources of proof for the alleged Congressional
intent were provided as follows:
First, the Findings section in DSHEA refers to the relationship between
dietary supplements and disease prevention. Second, section 403(r)(6) of the
act states that structure/functions statements 'claim' to treat or prevent
disease, and this term should be read to refer only to express claims. Third,
DSHEA requires structure/function claims to be accompanied by a
disclaimer that "this product is not intended to diagnose, treat, cure, or
prevent any disease." According to the comments, Congress understood that
specific disease treatment or prevention effects can also be described as
effects on the structure or function of the body and resolved the tension by
requiring the disclaimer.
Id.
186. See Steinborn & Todd, supra note 5, at 402.
187. See William Faloon, First Amendment Alert (visited Feb. 26, 1999)
<http:llwww.lef.org/magazine/mag98/aug98_cover.html>.
188. See id.
189. See generally Gilhooley, supra note 5, at 711-12 (offering, in part, a "better than" the
present rationale for an alternative regulatory scheme for dietary supplements).
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regulation. 190 Congress should amend the FDCA accordingly, creating a
new category of products called traditional herbal therapies. 191
Studies of St. John's Wort for depression and Kava Kava for anxiety
have consistently shown these herbal agents to have comparable efficacy to
synthetic tricyclic antidepressants and benzodiazepines, with fewer side
effects and less cognitive impairment. 192 Even before the FDA's final rule,
it was clear that DSHEA did not authorize claims such as "St. John's Wort
alleviates depression" or "Kava Kava can treat a panic disorder." 193 The
final rule, however, also interprets DSHEA as prohibiting claims that refer
to a characteristic set of signs or symptoms of a particular disease, even
when they do not name the actual disease. 94  Therefore, products
containing Kava Kava cannot contain a claim such as "Kava Kava relieves
anxiety."' 95 Likewise, products containing St. John's Wort cannot contain
a claim that "St. John's Wort reduces lack of appetite."' 96 However, the
final rule would still allow claims such as "Kava Kava can reduce stress
and frustration," and St. John's Wort can "bring balance to those who
experience mood swings and want to find equilibrium and harmony." 197 Of
190. See Guy Gugliotta, FDA Cancels Labeling Rule: Finns Told Not to Alarket Dietary
Products to Pregnant Women, WASH. POST, Feb. 10, 2000, at A2.
191. Professor Gilhooley advocates the creation of a special category of products called
supplemental products. See Gilhooley, supra note 5, at 719. She prefers that name over
traditional herbal remedies because it avoids having to develop criteria to determine what
makes something a traditional use. See id. at 718. Also, she prefers the term supplemental
products because it "helps to indicate that consumers should consider use in relationship to
the availability of tested drugs, and should consult their physician about continued use and
when the conditions worsens." Id. at 719. This author prefers the use of the term traditional
herbal remedies because it better reflects the wish of consumers to use herbs for traditional,
therapeutic purposes. It also better reflects (and validates) the use of herbs as alternative
therapies instead of just supplemental therapies. Gilhooley's concerns about consumer use
of herbs instead of, or in addition to, conventional therapies can be addressed with warning
and labeling requirements.
192. See Maureen Donohue, Kava Kava, St. John's Wort Similar to Drugs, CLINCAL
PSYCHIATRY NEWS, Jan. 1999, at 25.
193. See Dietary Supplement Health and Education Act of 1994, Pub. L. No. 103-417, § 6,
108 Stat. 4325, 4329 (1994) (codified as amended in scattered sections starting at 21 U.S.C.
§ 301 (1994)). DSHEA only authorizes structure/function claims; it forbids claims
describing disease prevention, treatment, or mitigation. See id.
194. See Final Rule, supra note 13, at 1015.
195. See id. at 1016. The FDA will focus on "whether specific signs and symptoms are
characteristic of a disease, based on objective sources." Id. Since anxiety is certainly a
recognized characteristic of anxiety disorder, the FDA would treat "Kava Kava relieves
anxiety" as a disease claim, or an impermissible structure-function claim. See id. However,
the FDA would allow Kava Kava manufacturers to claim that Kava Kava "relieves stress
and frustration." Id. Similarly, the FDA would allow the appropriate dietary supplement to
claim that it "helps to maintain cholesterol levels that are already within the normal range."
Id. at 1018. However, the dietary supplement product could not claim that the product





course, Kava Kava and St. John's Wort products bearing these claims must
also bear the disclaimer that these products aren't intended to "diagnose,
treat, cure or prevent any disease."' 98 But, as Dr. Varro E. Tyler, a well-
respected expert on herbs quips, "If this is true, why on earth would anyone
use it?"'199
DSHEA's aim was to increase the health options of consumers by
securing access to herbal and other supplements ,200 and increase
information about supplements to assist consumers in their decision to
incorporate supplements as part of their health regime.20 1 The final rule
moves in the direction of making it harder for consumers (as well as
physicians and pharmacists) to discern the health benefits of herbal
supplements. For the consumer who seeks to tum to herbal supplements to
help with anxiety or depressed mood, labeling claims like "reduces stress
and frustration" and "brings balance, equilibrium and harmony" vaguely
indicate the potential therapeutic benefits of products containing Kava
Kava and St. John's Wort. At best, such claims enable consumers to "take
a gamble" on the product, reasoning that these herbs might help them
out.2°2 Further, the final rule restricts herbal product manufacturers from
citing a title of a publication or other reference on product labeling, if the
title refers to a disease use.203 For example, if a St. John's Wort or Kava
Kava product included a reference to an article entitled, "Kava Kava, St.
John's Wort Similar to Drugs in the Treatment of Mild Depression and
Anxiety" on the immediate product label or packaging, it would create a
disease claim.2°
198. Dietary Supplement Health and Education Act § 6.
199. See Brody, Americans Gamble, supra note 1.
200. See Dietary Supplement Health and Education Act § 2.
201. See id.
202. See Brody, Americans Gamble, supra note 1.
203. See Final Rule, supra note 13, at 1050. Under §101.93(g)(2)(iv)(C), a statement
would be considered a disease claim if it:
Cit[ed] [] a publication or reference, if the citation refers to a disease use,
and if, in the context of the labeling as a whole, the citation implies
treatment or prevention of a disease, e.g., through placement on the
immediate product label or packaging, inappropriate prominence, or lack of
relationship to the product's express claims;
Id. The FDA will look at the "totality of all available labeling" to determine whether the use
of a scientific reference that refers to a disease use is permissible. Id. at 1024. One factor
the FDA will consider is the "prominence of the citation in the labeling." Id. The FDA
explains that:
If, -for example, the citation is simply listed in the bibliography section of the
labeling among other titles, it will generally not suggest an implied disease
claim. On the other hand, highlighting, bolding, using large type size, or
prominent placement of a citation that refers to a disease use in the title
could suggest that the product has an effect on disease.
Id.
204. See id. "The agency continues to believe that placing a citation to a scientific
reference that mentions a disease in the title on the immediate product label or packaging
should be considered a disease claim for that product, because of the unusual and
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The effect of the final rule is to prevent the informed use of herbal
supplements for therapeutic purposes. °5 It prohibits the use of claims on
herbal product labels that even suggest a beneficial relationship between
the use of a particular herb and disease, and it restricts the ability of herbal
manufacturers to guide consumers to publications describing those
benefits. 0 6 This is contrary to one of the purposes of DSHEA to empower
consumers "to make choices about preventive health care programs based
on data from scientific studies of health benefits related to particular dietary
supplements.20 7 It is also contrary to the trend that DSHEA started: to
remedy claims that have the potential to mislead with a stronger disclaimer
instead of proscribing the claim completely. 08 In Pearson v. Shalala, the
D.C. Circuit even went so far as to restrict the FDA from banning health
claims which were supported by evidence, albeit inconclusive evidence. 209
Recall that the D.C. Circuit court suggested that the correct remedy for
such "misleading" claims is to use a disclaimer.210 Otherwise, the FDA
would be in violation of the First Amendment.
This is not to say that all of the final rule is without merit. For
example, there is a section that prohibits the use of claims that explicitly or
implicitly claim that the product "[i]s a substitute for another product that is
a therapy for a disease." 21 2 The FDA offers "Herbal Prozac" and "Herbal
Phen-fen" as example of such claims.213 This section does not violate the
commercial speech doctrine because it is a good balance of the
government's interest in protecting consumers against the manufacturer's
interest in free speech. When herbal remedies can market themselves as
herbal alternatives to prescription drugs the danger that consumers will
forego proven, conventional therapies for unproven, alternative therapies is
compelling.21 4 As several organizations that commented on the proposed
version of this rule noted, associating dietary supplements with regulated
drug products is "deceptive and dangerous because it can signal to
consumers that because the product is 'herbal' it is safer."215  Further,
unnecessary prominence of such placement." See id.
205. See Faloon, supra note 187.
206. See id.
207. Dietary Supplement Health and Education Act of 1994, Pub. L. No. 103-417, §2(8),
108 Stat. 4325, 4326 (1994) (codified as amended in scattered sections starting at 21 U.S.C.
§ 301 (1994)).
208. See, e.g., Pearson, 164 F.3d at 657. "In more recent cases, the Court has reaffirmed





212. Final Rule, supra note 13, at 1050 (stating final rule to be codified as
§ 101.93(g)(2)(vi)).
213. See id. at 1027.
214. See Higgins, supra note 3, at 60-61.
215. Final Rule, supra note 13, at 1027.
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unlike the regulated drugs, manufacturers of claimed herbal substitutes do
not have to guarantee the potency of their products or describe indications
or contraindications for use. 216  Additionally, often the only way a
consumer can have access to regulated drugs is through the advice and
prescription of a doctor. The doctor as intermediary between the consumer
and the regulated drug is seen as essential to safe and effective use of the
drug. In contrast, consumers who choose the 'herbal substitute' are not
instructed on safe and effective use of the herbal therapy. Consequently,
nothing prevents the consumer from taking large doses of the 'herbal
alternative' in pursuit of a greater promised effect because of the false
sense of security that a lack of both warnings and need for prescription
217creates. Lastly, a disclaimer that reads that the product is not intended to
be a substitute for the regulated drug would not alleviate the public health
concerns such claims raise. Recalling Dr. Varro Tyler's quip, why would a
consumer use a product marketed as Herbal Prozac if it were true that it
was not intended to be a substitute for Prozac?
The interests of the consumer who wishes to use herbs as therapy
would be better served by a system that allowed herbs to be marketed as
traditional herbal therapies. Congress should amend the FDCA to include a
category of products called traditional herbal therapies, and establish a
framework for the creation of herbal monographs.218 There are a variety of
resources currently available which can assist the designated agency in its
task to create herbal monographs. Firstly, Medical Economics Company
has published a new Physicians' Desk Reference for Herbal Medicines.219
"Entries in the PDR for Herbal Medicine include scientific and common
names of herbs, along with indications, contraindications, dosages and
literature citations. ' 22° Secondly, the Office of Dietary Supplements at the
National Institutes of Health has just started a database of bibliographic
information on dietary supplements on the Internet.22 1 Also, Commission E
in Germany, which regulates herbal remedies, has developed herbal
medication monographs.222 And lastly, Congress recently replaced the
Office of Alternative Medicine with the National Center for
Complementary and Alternative Medicine (NCCAM).223 The goal was to
provide greater autonomy to initiate research projects on complementary
216. See Brody, Americans Gamble, supra note 1.
217. See supra notes 130-132 and accompanying text.
218. Edgar R. Cataxinos also advocated the use of herbal monographs in his proposal to
reform the regulation of herbal products, which he wrote before DSHEA was passed. See
Cataxinos, supra note 58, at 590.
219. Herbal PDR, 281 JAMA 314 (1999).
220. Id.
221. See Charles Marwick, Dietary Supplement Date on the Internet, 281 JAMA 313
(1999).
222. See Cataxinos, supra note 58, at 578.
223. See Arline Kaplan, National Center for Alternative Medicine Established,
PsYcHIATRic TIMES, Feb. 1999, at 36.
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and alternative medicine therapies 4.22  As a result, the NCCAM is another
resource for scientific data on herbal therapies.225 Congress could empower
NCAAM to create herbal monographs. Placing the authority to create
herbal monographs in the NCCAM would facilitate the entry of herbal
remedies into the mainstream, as 'complementary' (or even as an
alternative) to conventional medicine.
Herbal monographs should prescribe the therapeutic claims that herbal
manufacturers can make. For example, an herbal monograph for Feverfew,
an herb traditionally used to prevent fevers and that is also effective in
226preventing migraines, would allow products containing Feverfew to
make that claim as long as it conformed to carefully constructed warning
requirements. The monograph should require Feverfew herbal remedies
bearing the therapeutic claim to contain at least 0.2 percent
parthenolides. 27 The monograph should also require a recommended
dosage of 125 milligrams daily in a tablet or capsule. 2 8  In contrast,
Feverfew extract products could not bear a therapeutic claim because
studies have questioned whether the extract works.229 Further, the labeling
of Feverfew should explain that Feverfew must be taken daily to prevent
migraines because taking it only once a migraine starts is not effective.230
Feverfew, as well as all traditional herbal remedies, should also bear a
warning to consumers that they should inform their physician of the use of
the herbal remedy.
Herbal monographs should guarantee that the recommended use of the
herbal ingredient is safe.231 Also, herbal monographs should rate each herb
224. See id.
225. DSHEA mandated the creation of the Office of Dietary Supplements tODS). See
Dietary Supplement Health and Education Act of 1994, Pub. L. No. 103-417, § 13, 108 Stat.
4325, 4334 (1994) (codified as amended in scattered sections starting at 21 U.S.C. § 301
(1994)). ODS is responsible for researching dietary supplements and distributing the results
of its research. See id.; see also Lauren J. Sloane, Notes & Comments, Herbal Garden of
Good and Evil: The Ongoing Struggles of Dietary Supplement Regulation, 51 ADMIN. L.
REv. 323, 337 (1999). However, although DSHEA authorized $5 million annually for the
ODS, it has been underfunded at less than $1 million per year. Id. In contrast, the NCCAM
has a $50 million annual budget to study supplements and other nontraditional medical
practices. See Higgins, supra note 3, at 63.
226. See Bridget Doherty, What's Old is New-And Hotd, PREVENTION'S GUIDE: HEALING
HERBS, Mar. 2, 1999, at 75. See also Tanacetum Parthenium (Feverfew), in PDRO FOR
HERBALMEDICINES 1171, 1171-73 (Joerg Gruenwald et al. eds., 1998).
227. See Doherty, supra note 226 at 75. Studies on Feverfew which indicated positive
results involved doses containing 0.2 percent of parthenolides. See id. at 76.
228. See id. Therapeutic use of Feverfew requires this recommended dosage. Id.
229. See id.
230. See id.
231. As explained earlier, traditional use of an herbal ingredient is probative of safety. See
discussion infra Part mH. Cataxinos explains that a traditional use evaluation entails the
consideration of length of use, in addition to the medical and historical background of the
product. See Cataxinos, supra note 58, at 590 n.256. Further, Cataxinos argues that
traditional use would require a length of use for at least several decades. Id.
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on a scale from 1 to 5 for effectiveness. 232 A rating of '1' might indicate
that the herbal product conforms to traditional usage, but there exists only
anecdotal evidence in addition to the persistence of traditional use to
support effectiveness. A rating of '5' might indicate that there is
"significant scientific agreement" that the herbal product is effective for its
intended use. The agency given the authority to create herbal monographs
should periodically reassess its rating of a product to reflect the current
state of research. Further, a manufacturer of traditional herbal therapies
should be able to submit new scientific research to the agency and request
reassessment of the therapy's current rating.
Using a scale of 1 to 5 to indicate effectiveness would preserve access
to herbal products because even products that only met the first level of
effectiveness could enter the market with therapeutic claims. It would also
provide the consumer with an easy way to assess the effectiveness of a
product.233 Consumers who wish to use a traditional herbal therapy with a
rating of '1' will know that they should not rely on the herb as a substitute
for conventional medicine. However, that consumer could still seek its
benefits as a supplemental therapy to conventional medicine (unless the
herbal monograph warns against this) or as a preventive therapy.
Meanwhile, a rating of '5' would indicate to consumers that the
traditional herbal therapy is an effective product. Accordingly, they should
strictly adhere to the warnings and recommended dosage on the label that
are carefully crafted in the monograph. Products rated '5' should bear a
warning to consumers to consult a physician before use, in addition to the
warning advising consumers to inform their physician of use. Some
traditional herbal therapies might require a prescription for use because
safety concerns require it. A St. John's Wort product marketed as a therapy
for depression might be an example. In Germany, St. John's Wort requires
a prescription.234 The reasoning behind this is that diagnosis for depression
235
requires special skill and monitoring.
There are several advantages to an alternative regulatory scheme that
allows herbs to be marketed as traditional herbal therapies. Firstly, using a
numbered scale to evaluate the effectiveness of traditional herbal therapies
creates an incentive for herbal manufacturers to invest in research in an
effort to get a better rating. This would not only assist in the evaluation of
the effectiveness and safety of herbal therapies, but could help pave the
232. See Faloon, supra note 187. Durk Pearson and Sandy Shaw first proposed this
scheme of allowing a gradation of label claims, depending on the amount of evidence to
support the claim. See id. Pearson and Shaw were the plaintiffs/appellants in Pearson v.
Shalala. 164 F.3d 650, 650.
233. See Faloon, supra note 187.
234. See Brody, Americans Gamble, supra note 1.
235. See generally Martin, supra note 83, at 573 (explaining Canada's decision to ban
Gingko products because none of its intended uses were appropriate for nonprescription use;
they all required special training for diagnosis).
Winter 20001 A PROPOSAL
HASTINGS WOMEN'S LAW JOURNAL
way to identify which herbs will be the new, FDA-approved drugs of the
236future. Secondly, the category of traditional herbal therapies would not
be limited to products that can be ingested. This would create a space in
the market for topical herbal remedies, which are currently precluded from
entering the market as dietary supplements.237 Also, marketing herbal
remedies as traditional herbal therapies accompanied by the required
disclosures will encourage the use of herbal remedies in the mainstream.
Physicians and pharmacists will quickly be able to determine from the label
what the herbal remedy is intended to treat and how effective that treatment
is, allowing them to assess the advisability of recommending a particular
product to a patient.
Lastly, marketing herbal remedies as traditional herbal therapies would
eliminate the current difficulty the FDA is experiencing in trying to define
the line between DSHEA-authorized structure-function claims and disease
claims. For example, the FDA's proposed rule proscribed claims "that a
product had an effect on a condition associated with a natural state if the
condition presented 'a characteristic set of signs or symptoms recognizable
to health care professionals or consumers' as an 'abnormality' .' 238 The
FDA considered toxemia of pregnancy, premenstrual syndrome and hot
flashes as examples of such abnormal conditions.23 However, in its final
rule, the FDA narrowed its definition of abnormal conditions240 to permit
claims stating an effect on "hot flashes, common symptoms associated with
the menstrual cycle, [and] ordinary morning sickness associated with
pregnancy. ''241 The final rule continues to proscribe claims that state an
affect on toxemia of pregnancy. 242 The FDA acknowledged that the
proposed, broader definition for abnormal conditions was "not appropriate,
under DSHEA. 24 3 Some consumer advocates and health care providers
responded with concern to the final rule, fearing what untested dietary
supplements marketed to pregnant women might do to an unborn fetus.244
In response, the FDA disavowed part of the final rule, "warning companies
236. See, e.g., Data Watch: Herbal Remedies Being Evaluated Under an IND
Application, CLINICAL PSYCHIATRY NEWS, Jan. 1999, at 25. St. John's Wort and other herbs
are being evaluated to obtain new drug status. See id.
237. See, e.g., U.S. v. Ten Cartons, More or Less, of an Article.. .Energy B Vitamin B-
12, 888 F. Supp. 381, 395 (E.D.N.Y.), aff'd, 72 F.3d 285 (2d Cir. 1995) (district court held
that a gel fortified with vitamins and applied inside the nose was not a dietary supplement).
238. See Final Rule, supra note 13, at 1019.
239. See id.
240. See id. at 1050. The final rule, codified as 21 C.F.R. § 101.93(g)(2)dii), provides
that a statement claiming "an effect on an abnormal condition associated with a natural state
or process, if the abnormal condition is uncommon or can cause significant or permanent
harm," is a disease claim. Id.
241. See id. at 1000.
242. See id.
243. See Final Rule, supra note 13, at 1019.
244. See Gugliotta, supra note 190.
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not to promote their products as treatments for morning sickness, leg
swelling or any other condition affecting pregnant women."245 The effect
of this change in position is to revert to a broader definition of "abnormal
conditions." In light of the FDA's previous acknowledgement about a
broad definition of "abnormal conditions," it is unclear whether the
resulting definition is appropriate under DSHEA. The alternative
regulatory regime proposed in this Note would alleviate the regulatory
uncertainties DSHEA enacted. Instead of the current regime in which
herbal product manufacturers market their products as dietary supplements,
the proposed alternative regulatory regime would allow herbal product
manufacturers to make certain disease claims, while allowing the FDA to
meet safety and efficacy concerns by requiring the appropriate warnings
and disclosures.
CONCLUSION
DSHEA paved the way for herbal therapies to enter the mainstream of
health care in the United States as dietary supplements. It guaranteed
consumers' access to herbal remedies, and made published information
about the health benefits of those products available at the time of sale. As
the FDA currently implements DSHEA, however, the marketing of certain
herbal remedies (e.g., ephedra products) raises significant safety and
efficacy concerns. Further, DSHEA fails consumers who wish to use herbs
as therapy. For those consumers, it leaves them confused as to which
herbal product would best serve their health needs, which product conforms
to traditional, therapeutic use and what to expect in terms of effectiveness.
Creating an alternative regulatory category of traditional herbal
therapies that must conform to carefully crafted monographs for herbal
remedies promises a situation that is better than the present. It would allow
consumers, physicians and pharmacists to easily assess from the product
label what the therapeutic health benefits and risks of the product are, and
would provide a guarantee that those products are safe and conform to the
most effective therapeutic form of use that is currently recognized. Also, a
rating system of 1 to 5 for effectiveness would allow the consumer,
physician and pharmacist to rationally determine the extent to which they
should expect positive health benefits from an herbal remedy as well as the
extent to which they should rely on herbal remedies as opposed to
conventional therapies.
245. Id.
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